ExodusPoint Capital Management LP Boosts Stock Position in Repligen Co. (NASDAQ:RGEN)

ExodusPoint Capital Management LP boosted its holdings in shares of Repligen Co. (NASDAQ:RGEN) by 122.8% in the fourth quarter, Holdings Channel.com reports. The fund owned 213,718 shares of the biotechnology company’s stock after acquiring an additional 117,787 shares during the quarter. ExodusPoint Capital Management LP’s holdings in Repligen were worth $30,763,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of RGEN. Signaturefd LLC boosted its holdings in shares of Repligen by 172.2% in the fourth quarter. Signaturefd LLC now owns 196 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 124 shares during the period. Sava Infond d.o.o. purchased a new stake in shares of Repligen in the 4th quarter worth $29,000. Resources Management Corp CT ADV bought a new position in shares of Repligen during the 3rd quarter worth $37,000. Quarry LP increased its stake in shares of Repligen by 796.7% during the third quarter. Quarry LP now owns 269 shares of the biotechnology company’s stock valued at $40,000 after buying an additional 239 shares during the period. Finally, UMB Bank n.a. raised its holdings in shares of Repligen by 49.1% in the fourth quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company’s stock valued at $48,000 after acquiring an additional 110 shares in the last quarter. Institutional investors own 97.64% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have commented on the stock. JPMorgan Chase & Co. raised their target price on shares of Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a research report on Friday, February 21st. Evercore ISI began coverage on shares of Repligen in a report on Tuesday, March 18th. They set an “in-line” rating and a $155.00 price objective on the stock. Royal Bank of Canada upped their target price on Repligen from $203.00 to $205.00 and gave the stock an “outperform” rating in a report on Friday, February 21st. TD Cowen began coverage on Repligen in a research report on Monday, February 10th. They issued a “buy” rating and a $200.00 price target for the company. Finally, Canaccord Genuity Group raised their price objective on Repligen from $165.00 to $170.00 and gave the company a “hold” rating in a research report on Friday, February 21st. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $178.64.

Repligen Price Performance

Shares of RGEN opened at $130.92 on Thursday. The company’s fifty day moving average price is $152.03 and its 200-day moving average price is $147.88. The firm has a market capitalization of $7.35 billion, a PE ratio of -256.71, a price-to-earnings-growth ratio of 4.54 and a beta of 0.95. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76. Repligen Co. has a 1-year low of $113.50 and a 1-year high of $182.52.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings results on Thursday, February 20th. The biotechnology company reported $0.44 EPS for the quarter, beating the consensus estimate of $0.41 by $0.03. The company had revenue of $167.55 million for the quarter, compared to analyst estimates of $167.58 million. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. On average, equities research analysts predict that Repligen Co. will post 1.72 EPS for the current year.

Insider Buying and Selling

In other news, Director Margaret Pax acquired 250 shares of the company’s stock in a transaction dated Monday, March 17th. The shares were acquired at an average price of $150.69 per share, with a total value of $37,672.50. Following the purchase, the director now directly owns 1,043 shares of the company’s stock, valued at $157,169.67. This trade represents a 31.53 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. 1.20% of the stock is owned by corporate insiders.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.